.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,034,098

« Back to Dashboard

Details for Patent: 6,034,098

Title: Inhibitors of microsomal triglyceride transfer protein and method
Abstract:Compounds are provided which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases. The compounds have the structure ##STR1## wherein R.sup.1 to R.sup.7, Q, X and Y are as defined herein.
Inventor(s): Biller; Scott A. (Hopewell, NJ), Dickson; John K. (Eastampton, NJ), Lawrence; R. Michael (Yardley, PA), Magnin; David R. (Hamilton, NJ), Poss; Michael A. (Lawrenceville, NJ), Sulsky; Richard B. (Franklin Park, NJ), Tino; Joseph A. (Lawrenceville, NJ), Lawson; John E. (Wallingford, CT), Holava; Henry M. (Meriden, CT), Partyka; Richard A. (Neshanic, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Filing Date:Jul 21, 1997
Application Number:08/898,304
Claims:1. A compound which has the structure ##STR641## R.sup.8, R.sup.9 and R.sup.10 are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or cycloalkylalkyl;

R.sup.1 is a fluorenyl-type group of the structure ##STR642## R.sup.1 is an indenyl-type group of the structure ##STR643## Z.sup.1 and Z.sup.2 are the same or different and are independently a bond, O,S, ##STR644## with the proviso that with respect to B, at least one of Z.sup.1 and Z.sup.2 will be other than a bond; R.sup.11 is a bond, alkylene, alkenylene or alkynylene of up to 10 carbon atoms; arylene or mixed arylene-alkylene; R.sup.12 is hydrogen, alkyl, alkenyl, aryl, haloalkyl, trihaloalkyl, trihaloalkylalkyl, theteroaryl, arylalkyl, arylalkenyl, cycloalkyl, aryloxy, alkoxy, arylalkoxy or cycloalkylalkyl, with the proviso that

when R.sup.12 is H, aryloxy, alkoxy or arylalkoxy, then Z.sup.2 is ##STR645## Z is bond, O, S, N-alkyl, N-aryl, or alkylene or alkenylene from 1 to 5 carbon atoms; R.sup.13, R.sup.14, R.sup.15, and R.sup.16 are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cyclo-heteroalkyl, alkenyl, alkynyl, hydroxy, alkoxy, nitro, amino, thio, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkyl-carbonylamino, arylalkyl, heteroaryl, heteroarylalkyl or aryloxy;

R.sup.15a and R.sup.16a are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, alkoxy, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl, or aryloxy;

R.sup.2, R.sup.3, R.sup.4 are independently hydrogen, halo, alkyl, alkenyl, alkoxy, aryloxy, aryl, arylalkyl, alkylmercapto, arylmercapto, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, hydroxy or haloalkyl; ##STR646## are the same or different and are independently selected from heteroaryl containing 5- or 6-ring members; and

a pharmaceutically acceptable salt thereof.

2. The compound as defined in claim 1 having the formula ##STR647## and a pharmaceutically acceptable salt thereof.

3. The compound as defined in claim 1 wherein R.sup.1 is ##STR648##

4. The compound as defined in claim 3, wherein R.sup.1 is Z is a bond, O or S;

R.sup.13, R.sup.14, R.sup.15 and R.sup.16 are each H or one of R.sup.15 and R.sup.16 and one of R.sup.13 and R.sup.14 are halogen;

Z.sup.1 is a bond or C.dbd.O;

R.sup.11 is alkylene or alkenylene;

R.sup.12 -Z.sup.2 is ##STR649## R.sup.12a is alkyl, fluorinated lower alkyl or polyfluorinated lower alkyl.

5. The compound as defined in claim 1 having the structure ##STR650## Z is O, S or a bond; R.sup.13 and R15 are independently H or F;

Z.sup.1 is a bond;

R.sup.11 is alkylene;

R.sup.12 -Z.sup.2 is ##STR651## and R.sup.12a is alkyl, fluorinated lower alkyl or polyfluorinated lower alkyl.

6. The compound as defined in claim 5 wherein R.sup.11 is --(CH.sub.2).sub.4 --, Z.sup.1 is a bond, and R.sup.12 -Z.sup.2 is ##STR652##

7. The compound as defined in claim 5 having the structure where R.sup.13 and R.sup.15 are independently H or F, and R.sup.12 is trifluoromethylalkyl or alkyl.

8. The compound as defined in claim 1 having the structure ##STR653## where R.sup.12 is alkyl, and R.sup.13 and R.sup.15 are independently H or F.

9. The compound as defined in claim 1 wherein R.sup.1 is an indenyl-type group of the structure ##STR654## 10.

10. The compound as defined in claim 1 wherein R.sup.1 is a group of the structure

11. The compound as defined in claim 1 having the structure Z is O, S or a bond;

R.sup.13 and R.sup.15 are independently H or F;

Z.sup.1 is a bond;

R.sup.11 is alkylene;

R.sup.12 -Z.sup.2 is ##STR655## and R.sup.12a is alkyl, fluorinated lower alkyl or polyfluorinated lower alkyl.

12. The compound as defined in claim 1 which is:

2-[1-[2-(9H-fluoren-9-yl)ethyl]-4-piperidinyl]-2,3-dihydro-1H-isoindol-1-on e;

2,3-dihydro-2-[1-[2-[9-(2-propylenyl)-9H-fluoren-9-yl]ethyl]-4-piperidinyl] -1H-isoindol-1-one;

(Z)-2-[1-[4-(9H-fluoren-9-yl)-2-butenyl]-4-piperidinyl]-2,3-dihydro-1H-isoi ndol-1-one;

(Z)-2,3-dihydro-2-[1-[4-[9-(2-propenyl)-9H-fluoren-9-yl]-2-butenyl]-4-piper idinyl]-1H-isoindol-1-one;

and a pharmaceutically acceptable salt of any of the above and an N-oxide of any of the above.

13. The compound as defined in claim 1 which is ##STR656## 9-[3-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1 -piperidinyl]propyl]-N-propyl-9H-fluorene-9-carboxamide;

2,3-dihydro-2-[1-[4-oxo-4-(9-propyl-9H-fluoren-9-yl)butyl]-4-piperidinyl]-1 H-isoindol-1-one or its monohydrochloride salt;

(E)-9-[4-[4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-1-piperidinyl]-2-butenyl]- 2,7-difluoro-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide;

9-[4-[4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-1-piperidinyl]butyl]-2,7-diflu oro-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide;

(Z)-9-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]-2-butenyl]- N-propyl-9H-fluorene-9-carboxamide;

2,3-dihydro-2-[1-[2-oxo-2-(9-propyl-9H-fluoren-9-yl)ethyl]-4-piperidinyl]-1 H-isoindol-1-one;

(E)-9-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]-2-butenyl]- N-propyl-9H-fluorene-9-carboxamide;

9-[3-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]propyl]-N-propyl -9H-fluorene-9-carboxamide; ##STR657## N-[2-[4-(1,3-dihydro-1-oxo -2H-isoindol-2-yl)-1-piperidinyl]-ethyl]-9-propyl-9H-fluorene-9-carboxamide

9-[5-[4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-1-piperidinyl]pentyl]-N-propyl -9H-fluorene-9-carboxamide;

9-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]butyl]-N-(2,2,2- trifluoroethyl)-9H-fluorene-9-carboxamide;

9-[2-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]-ethyl]-N-propyl -9H-fluorene-9-carboxamide;

N-ethyl-9-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]butyl]-9 H-fluorene-9-carboxamide;

9-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]butyl]-N-2,2,2-t rifluoroethyl-9H-xanthene-9-carboxamide;

9-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]-butyl]-N-propyl -9H-xanthene-9-carboxamide;

9-[4-[4-(2,3-dihydro-1,3-dioxo-1H-isoindol-2-yl)-1-piperidinyl]butyl]-N-pro pyl-9H-fluorene-9-carboxamide;

9-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]butyl]-N-propyl- 9H-indeno[2,1-b]pyridine-9-carboxamide;

2,3-dihydro-2-[1-[4-hydroxy-4-(9-propyl-9H-fluoren-9-yl)butyl]-4-piperidiny l]-1H-isoindol-1-one;

2. 3-dihydro-2-[1-[3-[(9-propyl-9H-fluoren-9-yl)thio]propyl]-4-piperidinyl] -1H-isoindol-1-one;

2,3-dihydro-2-[1-[3-[(9-propyl-9H-fluoren-9-yl)sulfonyl]propyl]-4-piperidin yl]-1H-isoindol-1-one;

and a pharmaceutically acceptable salt of any of the above and an N-oxide of any of the above.

14. The compound as defined in claim 1 which is

2,3-dihydro-1-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]buty l]-N-propyl-1H-indene-1-carboxamide;

trans-2,3-dihydro-1-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidiny l]butyl]-2-phenyl-N-propyl-1H-indene-1-carboxamide;

1-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]butyl]-2-phenyl- N-propyl-1H-indene-1-carboxamide;

2-1-[4-[9-(butylsulfonyl)-9H-fluoren-9-yl]butyl]-4-piperidinyl]-2,3-dihydro -1H-isoindol-1-one;

9-[4-[[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)]-1-piperidinyl]butyl]-2,7 -difluoro-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide;

2,3-dihydro-2-[1-[4-[9-(1-oxopentyl)-9H-fluoren-9-yl]butyl]-4-piperidinyl]- 1H-isoindol-1-one;

9-[4-[4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]butyl]-N-(2,2,2- trifluoroethyl)-9H-fluorene-9-carboxamide;

9-[4-(4-(2,3-dihydro-1-oxo-1H-isoindol-2-yl)-1-piperidinyl]butyl]-N-(2,2,3, 3,4,4,4-heptafluorobutyl)-9H-fluorene-9-carboxamide;

1-[4-[4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-1-piperidinyl]butyl]-2-methyl- N-(2,2,2-trifluoroethyl)-1H-indene-1-carboxamide;

9-[4-[4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-1-piperidinyl]butyl]-N-(2,2,3, 3,3-pentafluoro-propyl)-9H-fluorene-9-carboxamide;

1-[4-[4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-1-piperidinyl]butyl]-N-(2,2,2- trifluoroethyl)-1H-indene-1-carboxamide;

and a pharmaceutically acceptable salt of any of the above and an N-oxide of any of the above.

15. A compound which has the structure ##STR658## R.sup.8, R.sup.9 and R.sup.10 are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or cycloalkylalkyl;

R.sup.1 is a fluorenyl-type group of the structure ##STR659## R.sup.1 is an indenyl-type group of the structure ##STR660## Z.sup.1 and Z.sup.2 are the same or different and are independently a bond, O, S, ##STR661## with the proviso that with respect to B, at least one of Z.sup.1 and Z.sup.2 will be other than a bond; R.sup.11 is a bond, alkylene, alkenylene or alkynylene of up to 10 carbon atoms; arylene or mixed arylene-alkylene; R.sup.12 is hydrogen, alkyl, alkenyl, aryl, haloalkyl, arylalkyl, arylalkenyl, cycloalkyl, trihaloalkyl, trihaloalkylalkyl, aryloxy, alkoxy, arylalkoxy or cycloalkylalkyl, with the proviso that

when R.sup.12 is H, aryloxy, alkoxy or arylalkoxy, then Z.sup.2 is ##STR662## and Z is bond, O, S, N-alkyl, N-aryl, or alkylene or alkenylene from 1 to 5 carbon atoms, R.sup.13, R.sup.14, R.sup.15, and R.sup.16 are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, hydroxy, alkoxy, nitro, amino, thio, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, carboxy, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl or aryloxy;

R.sup.15a and R.sup.16a are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, alkoxy, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl, or aryloxy;

R.sup.2, R.sup.3, R.sup.4 are independently hydrogen, halo, alkyl, haloalkyl, alkenyl, alkoxy, aryloxy, aryl, arylalkyl, alkylmercapto, arylmercapto, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, hydroxy or haloalkyl; ##STR663## are the same or different and are independently selected from heteroaryl containing 5- or 6-ring members; or

a pharmaceutically acceptable salt thereof.

16. A method for preventing, inhibiting or treating atherosclerosis; pancreatitis secondary to hypertriglyceridemia; or hyperglycemia (1) by causing reduced absorption of dietary fat through MTP inhibition or (2) by lowering triglycerides through MTP inhibition or (3) by decreasing absorption of free fatty acids through MTP inhibition; or obesity secondary to malabsorption of dietary fat in a mammalian species, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound as defined in claim 1.

17. A method of lowering serum lipid levels, cholesterol and/or triglycerides, or preventing and/or treating hyperlipemia, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia and/or hypertriglyceridemia, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound as defined in claim 1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc